| Revenue Growth | Medical Essentials 5.9%, Connected Care 2.1%, Biopharma 7%, Interventional 7.6%. |
|---|---|
| Mgmt Confidence | High confidence in 'New BD' strategy and sustainable mid-single digit growth. |
| Demand Visibility | Strong utilization in US; 100% attachment rate for new AI platform. |
| Order Book | Strong PICS Pro order momentum; won all six central fill opportunities. |
| Margin Trends | FY27 operating margins expected flat; 180bps gross margin expansion in Q4. |
| Op. Leverage | BD Excellence driving 8% gross productivity in plants; $200M cost-out program. |
| Pricing Power | Ability to increase prices used to mitigate inflationary headwinds. |
| Vol vs Price | Growth driven by share gains, utilization, and favorable product mix. |
| Segment Growth | Advanced Patient Monitoring and PureWick delivered double-digit growth. |
| New Clients | Landmark US government partnership; 100 biologic deals signed including Brazil pen. |
| Capex & Debt | $19B US investment commitment; $2.4B debt paid; 2.7x net leverage. |
| Regulatory | Section 232 tariff relief pending; FDA approval for Liberty Tip Stent. |
| Commentary | Shift to high-growth platforms creates a margin-accretive flywheel effect. |
| New Launches | BD VMAX, Liberty Tip Stent, Phasix ST Parastomal, Ancata AI platform. |
Growth
Q4 revenue grew 5.6% to $5.3B; Medical Essentials up 5.9%, Interventional up 7.6%.
Outlook
FY27 revenue growth guided low-single digits; adjusted EPS target $13.10 to $13.30.
Risks
Alaris capital comparison creates 200bps headwind for FY27; Q1 growth expected at low end.
The company's earnings call, NYSE: BDX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Becton Dickinson & Co: key numbers
- Share price
- $216.47Close, Nov 16
- Market cap
- $59B
- Shares outstanding
- 272.39MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Becton Dickinson & Co
All →Becton Dickinson & Chairman, CEO and President Thomas E. Polen Jr. Sells $629K of Stock
Thomas E. Polen Jr., Chairman, CEO and President, sold 2,993 shares of Becton Dickinson & Co at $210.00 a share, worth $629K in total on Nov 5, 2026. Shares held after the trade: 110,163 (-2.6%).
- Value
- $629K
- Shares
- 2,993
- Price
- $210.00
- Role
- Chairman, CEO and President
- Holding change
- -2.6%
- Trade date
- Nov 5, 2026
Becton Dickinson & Financial Results
Becton, Dickinson and Company (BD) reported Q4 fiscal 2026 revenue of $5.3 billion, a 5.4% increase, and full-year revenue of $19.5 billion. The company highlighted the completion of its transformation into a more focused MedTech company following the separation of its Life Sciences business and issued guidance for fiscal 2027.
“We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms. Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business. We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD.”
Tom Polen, chairman, CEO and president of BD
Becton Dickinson & EVP, Chief Revenue Officer Michael Feld Sells $15.1K of Stock
Michael Feld, EVP, Chief Revenue Officer, sold 76 shares of Becton Dickinson & Co at $198.13 a share, worth $15.1K in total on Oct 26, 2026. Shares held after the trade: 19,568 (-0.4%).
- Value
- $15.1K
- Shares
- 76
- Price
- $198.13
- Role
- EVP, Chief Revenue Officer
- Holding change
- -0.4%
- Trade date
- Oct 26, 2026
Becton Dickinson & EVP, Chief Revenue Officer Michael Feld Sells $14K of Stock
Michael Feld, EVP, Chief Revenue Officer, sold 76 shares of Becton Dickinson & Co at $183.70 a share, worth $14K in total on Sep 28, 2026. Shares held after the trade: 19,644 (-0.4%).
- Value
- $14K
- Shares
- 76
- Price
- $183.70
- Role
- EVP, Chief Revenue Officer
- Holding change
- -0.4%
- Trade date
- Sep 28, 2026